MX2018011721A - Compuesto de griseofulvina. - Google Patents
Compuesto de griseofulvina.Info
- Publication number
- MX2018011721A MX2018011721A MX2018011721A MX2018011721A MX2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- alkyl group
- griseofulvina
- acceptable salt
- formula
- Prior art date
Links
- -1 GRISEOFULVINA COMPOUND Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un objeto de la presente invención es proporcionar un compuesto que tiene una actividad antiinflamatoria o una sal farmacológicamente aceptable del mismo. La solución de la presente invención es un compuesto de la fórmula general (1) o una sal farmacológicamente aceptable del mismo. (ver Fórmula) en donde los símbolos en la fórmula se definen a continuación: R1: por ejemplo, un grupo C1-C6alquilo; R2: un grupo C1-C6alquilo; A: por ejemplo, un átomo de oxígeno; y R3: por ejemplo, un grupo C1-C6alquilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016067076 | 2016-03-30 | ||
| PCT/JP2017/012777 WO2017170623A1 (ja) | 2016-03-30 | 2017-03-29 | グリセオフルビン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011721A true MX2018011721A (es) | 2019-01-10 |
| MX385971B MX385971B (es) | 2025-03-18 |
Family
ID=59965779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011721A MX385971B (es) | 2016-03-30 | 2017-03-29 | Compuesto de griseofulvina. |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US10570109B2 (es) |
| EP (2) | EP4032883A1 (es) |
| JP (1) | JP6808715B2 (es) |
| KR (1) | KR102419232B1 (es) |
| CN (1) | CN108779089B (es) |
| AU (1) | AU2017244777B2 (es) |
| BR (1) | BR112018069712B1 (es) |
| CA (1) | CA3018316C (es) |
| CO (1) | CO2018010787A2 (es) |
| DK (1) | DK3438103T3 (es) |
| ES (1) | ES2908221T3 (es) |
| HU (1) | HUE058182T2 (es) |
| IL (1) | IL262020B (es) |
| MX (1) | MX385971B (es) |
| MY (1) | MY195881A (es) |
| PH (1) | PH12018502012B1 (es) |
| PL (1) | PL3438103T3 (es) |
| PT (1) | PT3438103T (es) |
| RU (1) | RU2736208C2 (es) |
| SG (1) | SG11201808171PA (es) |
| TW (1) | TWI738751B (es) |
| WO (1) | WO2017170623A1 (es) |
| ZA (1) | ZA201807129B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108779089B (zh) | 2016-03-30 | 2022-04-29 | 第一三共株式会社 | 灰黄霉素化合物 |
| TWI811243B (zh) * | 2017-09-29 | 2023-08-11 | 日商第一三共股份有限公司 | 灰黃黴素化合物及醫藥用途 |
| CN108329291B (zh) * | 2018-01-31 | 2021-07-09 | 青岛理工大学 | 一种离子液体催化的9-蒽酮内酯类化合物的合成方法 |
| WO2021202822A1 (en) * | 2020-04-02 | 2021-10-07 | Sirtsei Pharmaceuticals, Inc. | Compositions and methods for treating age-related diseases and premature aging disorders |
| CN113861144B (zh) * | 2021-08-04 | 2022-06-21 | 南通大学 | 一种灰黄霉素开环衍生物及其制备方法 |
| CN116199657B (zh) * | 2023-02-20 | 2024-11-29 | 延安大学 | 灰黄霉素4位醚化衍生物及其应用 |
| CN117229246B (zh) * | 2023-05-23 | 2024-06-07 | 湖北天勤生物科技股份有限公司 | 具有抗炎活性的化合物及其制备方法和用途 |
| WO2025135109A1 (ja) * | 2023-12-20 | 2025-06-26 | 第一三共株式会社 | グリセオフルビン化合物の結晶、該化合物の精製方法、及び該化合物に関する製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03255081A (ja) * | 1990-03-01 | 1991-11-13 | Mect Corp | ｄｌ―グリセオフルビン、ｄｌ―グリセオフルビン誘導体およびそれらの中間体の製造方法 |
| DE4430910A1 (de) | 1994-08-31 | 1996-03-07 | Eisele Rolf Dipl Ing Fh | Arzneimittel gegen Tinnitus |
| WO2003092617A2 (en) | 2002-05-03 | 2003-11-13 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory skin disorders |
| EP2008652A1 (en) * | 2007-06-28 | 2008-12-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
| EP2204367A1 (en) | 2008-12-22 | 2010-07-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
| WO2010124695A1 (fr) | 2009-04-26 | 2010-11-04 | Soumia Goutali | Utilisation de la griseofulvine dans l'amelioration des facultes mentales: attention, concentration et memoire |
| US9416143B2 (en) * | 2012-08-01 | 2016-08-16 | Pierre Fabre Medicament | Griseofulvin derivatives |
| CN104860909B (zh) * | 2015-04-09 | 2017-03-08 | 西北农林科技大学 | 灰黄霉素衍生物、灰黄霉素及其衍生物的抗菌活性应用 |
| CN108779089B (zh) | 2016-03-30 | 2022-04-29 | 第一三共株式会社 | 灰黄霉素化合物 |
| TWI811243B (zh) | 2017-09-29 | 2023-08-11 | 日商第一三共股份有限公司 | 灰黃黴素化合物及醫藥用途 |
-
2017
- 2017-03-29 CN CN201780017933.3A patent/CN108779089B/zh active Active
- 2017-03-29 PL PL17775160T patent/PL3438103T3/pl unknown
- 2017-03-29 BR BR112018069712-5A patent/BR112018069712B1/pt active IP Right Grant
- 2017-03-29 PT PT177751609T patent/PT3438103T/pt unknown
- 2017-03-29 US US16/088,696 patent/US10570109B2/en active Active
- 2017-03-29 RU RU2018137851A patent/RU2736208C2/ru active
- 2017-03-29 TW TW106110433A patent/TWI738751B/zh active
- 2017-03-29 MY MYPI2018001614A patent/MY195881A/en unknown
- 2017-03-29 EP EP21212977.9A patent/EP4032883A1/en active Pending
- 2017-03-29 EP EP17775160.9A patent/EP3438103B1/en active Active
- 2017-03-29 PH PH1/2018/502012A patent/PH12018502012B1/en unknown
- 2017-03-29 JP JP2018508114A patent/JP6808715B2/ja active Active
- 2017-03-29 WO PCT/JP2017/012777 patent/WO2017170623A1/ja not_active Ceased
- 2017-03-29 SG SG11201808171PA patent/SG11201808171PA/en unknown
- 2017-03-29 DK DK17775160.9T patent/DK3438103T3/da active
- 2017-03-29 HU HUE17775160A patent/HUE058182T2/hu unknown
- 2017-03-29 CA CA3018316A patent/CA3018316C/en active Active
- 2017-03-29 AU AU2017244777A patent/AU2017244777B2/en active Active
- 2017-03-29 KR KR1020187027758A patent/KR102419232B1/ko active Active
- 2017-03-29 ES ES17775160T patent/ES2908221T3/es active Active
- 2017-03-29 MX MX2018011721A patent/MX385971B/es unknown
-
2018
- 2018-09-27 IL IL262020A patent/IL262020B/en unknown
- 2018-10-08 CO CONC2018/0010787A patent/CO2018010787A2/es unknown
- 2018-10-25 ZA ZA2018/07129A patent/ZA201807129B/en unknown
-
2019
- 2019-09-05 US US16/561,459 patent/US10654821B2/en active Active
-
2020
- 2020-04-09 US US16/844,621 patent/US10975052B2/en active Active
-
2021
- 2021-03-25 US US17/212,373 patent/US11472784B2/en active Active
-
2022
- 2022-10-13 US US18/046,270 patent/US11834427B2/en active Active
-
2023
- 2023-11-03 US US18/501,481 patent/US12091395B2/en active Active
-
2024
- 2024-08-29 US US18/819,139 patent/US20250059151A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011721A (es) | Compuesto de griseofulvina. | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| CO2020003114A2 (es) | Compuesto que tiene estructura ciclica | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CR20160296A (es) | Benzamidas sustituidas y métodos para usarlas | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| CY1120682T1 (el) | Ενωσεις για την προστασια κυτταρων | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CR20190504A (es) | COMPUESTO DE AMIDA (Divisional 2015-0454) | |
| AR101690A1 (es) | Composiciones tensioactivas acuosas | |
| AR100049A1 (es) | Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 | |
| CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR103316A1 (es) | Inhibidores de dihidroquinazolina de terminasa viral | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| JO3264B1 (ar) | مركبات ازيتيدينيل أوكسي فينيل بيروليدين | |
| AR104539A1 (es) | Compuestos cíclicos |